3 ms·

Nope, you're the one who's wrong. What nicwilson said is exactly right. Without an adjuvant, unless the vaccine itself happens to stimulate innate immunity, thi

Nope, you're the one who's wrong. What nicwilson said is exactly right. Without an adjuvant, unless the vaccine itself happens to stimulate innate immunity, this would end up inducing immunological tolerance. It is true that if you have a strong adjuvant, you could get away with smaller doses of the antigen, which is good for pandemic vaccines. Source: Charles Janeway, "Approaching the asymptote? Evolution and revolution in immunology," http://symposium.cshlp.org/content/54/1.long http://symposium.cshlp.org/content/54/1.long P.S. I wrote a COVID adjuvant grant this past spring, and my mother studies immunological tolerance. So if you disagree can you at least share some sources?

rolph 6y ago
the fact that i am still alive, the fact that people survive infection and produce antibodies are salient. you are wrong, and its right in front of you. please tell me about KNO3 please tell me about priming and boosting. please tell me about innate humoral response, and cell mediated response. i see you are still a student. once again vaccines are not obligated to adjuvents adjuvents increase the response to a signal allowing a weaker signal to evoke a response of threshold level. the economic and practical bounds incurred by the expense of the immunogenic product are offset by thus exploiting, the biological property of amplification we can spread out the materials to make many more doses of vaccine requireing fewer "boost" dosages. the big angle to work is the lack of cytoplasmic Vir-mRNA of immunogenic character. the current S protien production system is a get it shipping now product, with more work we can produce a sequence that stimulates cytoplasmic processes also involved in the induction of primary immune response. the current sequence doesnt do that. have a look here and see where this is heading : https://pubmed.ncbi.nlm.nih.gov/27252702/ https://pubmed.ncbi.nlm.nih.gov/27252702/ Interferon production at scale is tedious to say the least, it is superior to induce in vivo interferon dynamics, along with immunogenic antigen translation.

rolph 6y ago

the fact that i am still alive, the fact that people survive infection and produce antibodies are salient. you are wrong, and its right in front of you. please tell me about KNO3 please tell me about priming and boosting. please tell me about innate humoral response, and cell mediated response. i see you are still a student. once again vaccines are not obligated to adjuvents adjuvents increase the response to a signal allowing a weaker signal to evoke a response of threshold level. the economic and practical bounds incurred by the expense of the immunogenic product are offset by thus exploiting, the biological property of amplification we can spread out the materials to make many more doses of vaccine requireing fewer "boost" dosages. the big angle to work is the lack of cytoplasmic Vir-mRNA of immunogenic character. the current S protien production system is a get it shipping now product, with more work we can produce a sequence that stimulates cytoplasmic processes also involved in the induction of primary immune response. the current sequence doesnt do that. have a look here and see where this is heading : https://pubmed.ncbi.nlm.nih.gov/27252702/ https://pubmed.ncbi.nlm.nih.gov/27252702/ Interferon production at scale is tedious to say the least, it is superior to induce in vivo interferon dynamics, along with immunogenic antigen translation.